EXPLORE!

FDA Clears Pembrolizumab for Adjuvant Treatment of Kidney Cancer

  644 Views

#Nephrology  #Oncology  #Pathology and Lab Medicine  #Public Health 

eMediNexus    19 November 2021

The US FDA has granted approval to pembrolizumab for the adjuvant treatment of renal cell carcinoma (RCC) for those patients who have an intermediate-high or high risk of recurrence after nephrectomy, or after nephrectomy and metastatic lesion resection.

The approval has come after the KEYNOTE-564 trial showed that adjuvant treatment with pembrolizumab after nephrectomy led to a significant improvement in disease-free survival (DFS). About 22% of patients receiving immunotherapy had events of recurrence or death compared to 30% of patients in the placebo group (HR 0.68, 95% CI 0.53-0.87, P=0.001). This was a multicenter, randomized, double-blind, placebo-controlled trial that included 994 patients with intermediate-high or high risk of RCC recurrence, or stage M1 with no disease evidence… (Medpage Today)

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.